Limbic and associated brain peptide fraction A — RU2503457C2
N. N. Karkishchenko, V. N. Karkishchenko, S. L. Lyublinskiy · 2014 · RU2503457C2 · patent family 49253701
Published 2014-01-10.
Related evidence maps: Sports performance ↗
Reported patent results
Reported findings
The patent reports day-21 cycling sprint times of about 6.8 versus 4.6 minutes and swimming endurance of 34 versus 23 minutes. The athlete tables overlap the related paired-fraction filing.
The patent reports two cycling groups of six trained volunteers aged 20–22, with a 20 mg rectal dose versus saline. Rat treadmill groups had 12 animals each and received 0.5 mg per animal rectally versus saline. Mini-pig groups had six each, with 0.56 mg/kg rectally versus placebo.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cyclists · day-21 sprint to exhaustion | 6.8 ± 0.2 vs 4.6 ± 0.5 min | Fraction A versus saline, six per group. Cross-checked against the matching Fraction A table in the paired filing. The standalone electronic text drops decimal separators in several cells. |
| Cyclists · day-21 submaximal distance | 12,800 ± 150 vs 7,100 ± 100 m | Fraction A versus saline. Active-arm starting distance was 7,600 m versus 6,300 m in controls. |
| Swimmers · day-21 endurance | 34.0 ± 2 vs 23.0 ± 5 min | Fraction A versus saline, as printed in Table 8. The standalone swim example does not state its arm sizes. |
| Rat hypoxia · day-22 time to agonal breathing | 285.8 ± 9.0 vs 107.1 ± 6.3 s | Simulated altitude of 11,500 m. Day-1 means were 95.8 and 105.8 s, respectively. |
| Rat treadmill · day-21 duration | 205 ± 19 vs 133 ± 13 s | The active arm also declined from its own day-1 mean of 263 seconds. |
| Mini-pig treadmill · day-21 duration | 31.6 ± 1.4 vs 28.2 ± 0.9 min | Six per group. Day-1 means were 27.0 and 26.6 min, respectively. |
Selected comparisons reported by the applicant
| Endpoint | Day | Fraction A | Control |
|---|---|---|---|
| Rat treadmill (s) | 21 | 205 ± 19 | 133 ± 13 |
| Rat hypoxia (s) | 22 | 285.8 ± 9.0 | 107.1 ± 6.3 |
| Mini-pig treadmill (min) | 21 | 31.6 ± 1.4 | 28.2 ± 0.9 |
| Cycling sprint (min) | 21 | 6.8 ± 0.2 | 4.6 ± 0.5 |
| Cycling distance (m) | 21 | 12,800 ± 150 | 7,100 ± 100 |
| Swim endurance (min) | 21 | 34.0 ± 2 | 23.0 ± 5 |
The corresponding patent examples are small and incompletely reported. These values do not establish a new cohort or a clinical effect estimate.
The cycling sprint and distance series and the swim endurance series match the corresponding arms in RU2503459C2 closely enough to treat them as overlapping disclosures. Table 9 also prints an extra unlabeled speed series. The standalone filing leaves allocation, masking and systematic harms unclear.
Source for these results ↗ · Reviewed 2026-11-11
Patent claims and provenance
Formulation. A 2–5 kDa peptide fraction from specified hippocampal, cingulate, amygdalar, caudate and hypothalamic tissue of young cattle or pigs. The claim specifies 5–10 mg/mL in aqueous solution or 5–10 mg/g in a Witepsol suppository.
The athlete results substantially repeat the Fraction A and saline series in RU2503459C2. The filing does not identify VIR-8, Pept-8 or Pep-8 as the claimed fraction.
- Publication
- RU2503457C2 ↗ · 2014-01-10
- Earliest priority / filing
- 2012-03-22 / 2012-03-22
- Original applicant / assignee
- Scientific Center for Biomedical Technologies, Russian Academy of Medical Sciences
- Indexed status
- IP right cessation in Google Patents · checked 2026-11-11
- Patent family
- 49253701 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Средство для стимуляции работы в экстремальных условиях
Inventors: N. N. Karkishchenko; V. N. Karkishchenko; S. L. Lyublinskiy.
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The athlete results substantially repeat the Fraction A and saline series in RU2503459C2. The filing does not identify VIR-8, Pept-8 or Pep-8 as the claimed fraction.
- The cycling sprint and distance series and the swim endurance series match the corresponding arms in RU2503459C2 closely enough to treat them as overlapping disclosures. Table 9 also prints an extra unlabeled speed series. The standalone filing leaves allocation, masking and systematic harms unclear.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Available format: Original patent text and indexed metadata
Material reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related publications may cover the same research program or participants.
Source access
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Source reviewed 2026-11-11.
Source type: Patent publication
Citation and original source
Original source: N. N. Karkishchenko, V. N. Karkishchenko, S. L. Lyublinskiy. Limbic and associated brain peptide fraction A — RU2503457C2 RU2503457C2 · patent family 49253701 2014.
Molekul research summary: https://molekul.io/research/patent-ru2503457c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry